ClinicalTrials.gg
Not yet recruitingNCT07634874Updated Jun 9, 2026

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese Participants

A Phase 1 interventional study of KH607 and KH607 in Food Effect of KH607 in Chinese Health Participants, sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a randomized, open-label, 2-period, 2-sequence, crossover food-effect study designed to evaluate the effect of a high-fat meal on the pharmacokinetics of a single oral dose of KH607 tablets in healthy participants, as well as to assess the safety of a single oral dose of KH607 tablets administered under fasting and fed conditions in healthy participants.

02

Conditions studied

  • Food Effect of KH607 in Chinese Health Participants
03

In context

Lead sponsor

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be healthy and aged ≥18 and \<45 years at the time of screening visit.
  2. Participants must have a body weight equal to or greater than 50 kg (≧45 kg for females ) and a between 19.0 kg/m2 and 28.0 kg/m2 at the time of screening visit.
  3. Participants who have no plans for reproduction during the study period and for 3 months following the last dose, must voluntarily agree to use effective and appropriate measures, and must have no plans for sperm or egg donation during this period.
  4. Participant who can understand and comply with the study procedures and requirements, and can provide written prior to any study procedures shall be included

Exclusion criteria

Exclusion Criteria:

  1. Participants with known allergy to any ingredient of KH607; or those with a known history of allergy to drugs of the same class; or those with known allergies to two or more other drugs, foods, or environmental factors; or those known to be prone to allergic symptoms such as rash, urticaria, etc. shall be excluded.
  2. Participants with diseases of the cardiovascular, nervous, respiratory, urinary, digestive, hematologic, endocrine, or immune systems, or psychiatric disorders (including but not limited to: history of epilepsy, Parkinson's disease or other movement disorders, history of syncope or vertigo, and any history of psychiatric disorders), which may affect the safety evaluation of the trial, and who, in the opinion of the investigator, are unsuitable for participation in the trial.
  3. Participants with a history of vestibular dysfunction or severe motion sickness; or a history of ocular disorders such as glaucoma, retinopathy, or other ophthalmic diseases that may cause blurred vision or exacerbate visual adverse effects and are considered clinically significant by the investigator shall be excluded.
  4. Participants who are unable to Irefrain from driving vehicles, operating hazardous machinery, or working at heights from the time of signing the form until 1 week after the last dose shall be excluded.
  5. Participation who have participated in another clinical trial and received an drug, vaccine, or device within 90 days prior to the first dose shall be excluded.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Sequence A: KH607

    period 1: Fasted, Period 2: Fed

    Drug: KH607

  • Experimental
    Sequence B: KH607

    period 1: Fed, Period 2: Fasted

    Drug: KH607

Interventions

  • DrugKH607

    KH607, single dose, oral

  • DrugKH607

    KH607, single dose, oral

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Time frame: Up to 96 Hours after study drug administration

  2. AUC0-∞

    Time frame: Up to 96 Hours after study drug administration

  3. Cmax

    Time frame: Up to 96 Hours after study drug administration

  4. The GMRs and their 90% confidence intervals for AUC0-∞ (or AUC0-t and Cₘₐₓ of KH607 tablets under fasting and fed conditions )

    Time frame: Up to 96 Hours after study drug administration

Secondary outcomes

  1. Tmax

    Time frame: Up to 96 Hours after study drug administration

  2. t1/2

    Time frame: Up to 96 Hours after study drug administration

  3. λz

    Time frame: Up to 96 Hours after study drug administration

  4. tlag

    Time frame: Up to 96 Hours after study drug administration

  5. CL/F

    Time frame: Up to 96 Hours after study drug administration

  6. Safety:Incidence and severity of Adverse Events ( AE)/SAE

    Time frame: from ICF signing date to day 19 since first dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jul 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 9, 2026
StartEst.
Jun 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07634874
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jun 9, 2026

Study contacts

Chang Meng Yang, Medical Doctor
Contact
ymc681@126.com
86-28-87393401

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KH607

Start the discussion